We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bacteriophages Delivered by Dry Powder Cure Lung Diseases in Model

By LabMedica International staff writers
Posted on 03 Aug 2018
A novel antibacterial transport system utilized a dry powder approach to deliver microparticles coated with bacteriophages to difficult to access areas in the lungs.

Lung infections associated with pneumonia, or cystic fibrosis caused by Pseudomonas aeruginosa or other bacteria, result in significant morbidity and mortality, in part owing to the development of multidrug resistance, also against last-resort antibiotics. More...
Lytic bacteriophages (viruses that specifically kill bacteria) can reduce lung-associated infections, yet their clinical use is hindered by difficulties in delivering active phages to the deep lung.

To solve the problem of phage transport, investigators at the Georgia Institute of Technology (Atlanta, USA) developed microparticle carriers fabricated from the same polymer material used in dissolving sutures. These porous particles were made to be large enough to avoid rapid clearance by the body, but light enough to be delivered deep into the lungs. Phages were incubated with the particles, which were then dried.

The investigators reported in the July 16, 2018, online edition of the journal Nature Biomedical Engineering that phage-loaded polymeric microparticles deposited throughout the lungs via dry powder inhalation delivered active phages. These phage-loaded microparticles effectively reduced P. aeruginosa infections and the associated inflammation in wild-type and cystic fibrosis transmembrane-conductance-regulator knockout mice, and rescued the mice from pneumonia-associated death. The phage-coated microparticles were more effective at clearing bacteria than dried phage particles by themselves. The polymer material was biodegradable and was cleared from the animals within a few days.

“When we immobilized the phage on the particles, we could retain good activity for days – as long as two weeks at room temperature. We could store these particles, and when we delivered them to mice, get good distribution through the lungs. We believe the particles help stabilize the phage and improve the distribution in the lungs,” said senior author Dr. Andrés García, professor of mechanical engineering at the Georgia Institute of Technology. “Phage delivery is an area where the right type of material could make a difference in therapeutic applications. We set out to engineer a biomaterial carrier that would keep the phage active while delivering them deep into the lungs in a uniform fashion. This is a key step in moving this potential therapy forward.”

Related Links:
Georgia Institute of Technology


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.